Heidi Simmons

816 total citations
11 papers, 596 citations indexed

About

Heidi Simmons is a scholar working on Molecular Biology, Cell Biology and Genetics. According to data from OpenAlex, Heidi Simmons has authored 11 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Cell Biology and 3 papers in Genetics. Recurrent topics in Heidi Simmons's work include Microtubule and mitosis dynamics (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Heidi Simmons is often cited by papers focused on Microtubule and mitosis dynamics (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Protein Degradation and Inhibitors (3 papers). Heidi Simmons collaborates with scholars based in United States, Canada and United Kingdom. Heidi Simmons's co-authors include Kevin Litwiler, Clive Morris, Lorelei J. Hanson, Sabine Eckhardt, Lara Maloney, Stephen Leong, David M. Wilson, Laura Q.M. Chow, Katie Kane and Alex A. Adjei and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Heidi Simmons

9 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heidi Simmons United States	4	446	296	102	87	64	11	596
Eli Wallace United States	9	538 1.2×	296 1.0×	66 0.6×	111 1.3×	106 1.7×	16	697
Andrew E. Aplin United States	15	604 1.4×	363 1.2×	71 0.7×	91 1.0×	75 1.2×	22	722
Wayne Blosser United States	15	464 1.0×	310 1.0×	55 0.5×	54 0.6×	95 1.5×	19	637
Marian M. Deuker United States	6	580 1.3×	274 0.9×	71 0.7×	118 1.4×	65 1.0×	6	742
Joe Lyssikatos United States	6	380 0.9×	207 0.7×	42 0.4×	87 1.0×	80 1.3×	8	502
Michael B. Atkins United States	9	507 1.1×	507 1.7×	39 0.4×	39 0.4×	79 1.2×	14	761
Wai Lin Wong United States	2	461 1.0×	324 1.1×	40 0.4×	113 1.3×	163 2.5×	4	681
Rosalin Mishra United States	11	421 0.9×	345 1.2×	37 0.4×	56 0.6×	139 2.2×	20	724
Weiming Gai United States	10	432 1.0×	171 0.6×	59 0.6×	31 0.4×	39 0.6×	11	548
Annette S. Little United Kingdom	8	431 1.0×	165 0.6×	30 0.3×	72 0.8×	40 0.6×	8	499

Countries citing papers authored by Heidi Simmons

Since Specialization

Citations

This map shows the geographic impact of Heidi Simmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Simmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Simmons more than expected).

Fields of papers citing papers by Heidi Simmons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Simmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Simmons. The network helps show where Heidi Simmons may publish in the future.

Co-authorship network of co-authors of Heidi Simmons

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Simmons. A scholar is included among the top collaborators of Heidi Simmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Simmons. Heidi Simmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Mangoff, Kathryn, Rebecca F. McClure, Mona Shafey, et al.. (2024). Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses. Blood. 144(Supplement 1). 6291–6291.

Lai, Catherine, et al.. (2024). Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease. Clinical Lymphoma Myeloma & Leukemia. 24(9). 634–641. 1 indexed citations

Simmons, Heidi, et al.. (2023). Impact of Sequence Uniqueness on MRD Monitoring in NGS Immunoglobulin Sequencing: An Analysis of Ig Loci Among >1200 Diffuse Large B-Cell Lymphoma Patients Tested By Clonoseq. Blood. 142(Supplement 1). 5029–5029.

Berinstein, Neil L., Kathryn Mangoff, Rebecca F. McClure, et al.. (2023). Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM). Blood. 142(Supplement 1). 3037–3037. 2 indexed citations

Kubicki, Tadeusz, Heidi Simmons, Aimaz Afrough, et al.. (2023). Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd). Blood. 142(Supplement 1). 1982–1982. 2 indexed citations

LoRusso, Patricia, Priscila Gonçalves, Kevin Litwiler, et al.. (2015). First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 33(2). 440–449. 40 indexed citations

Khoury, H. Jean, Guillermo Garcia‐Manero, Gautam Borthakur, et al.. (2011). A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer. 118(14). 3556–3564. 56 indexed citations

Gonçalves, Priscila, E. A. Sausville, Martin J. Edelman, et al.. (2010). A phase I study of ARRY-520 in solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2570–2570. 1 indexed citations

Garcia‐Manero, Guillermo, H. Jean Khoury, Gautam Borthakur, et al.. (2009). A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.. Blood. 114(22). 2047–2047. 2 indexed citations

10.

Adjei, Alex A., Roger B. Cohen, Wilbur A. Franklin, et al.. (2008). Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers. Journal of Clinical Oncology. 26(13). 2139–2146. 476 indexed citations

11.

Simmons, Heidi, et al.. (2005). Identification of NOM1, a nucleolar, eIF4A binding protein encoded within the chromosome 7q36 breakpoint region targeted in cases of pediatric acute myeloid leukemia. Gene. 347(1). 137–145. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact